[The prevalence of cytostatic-resistant lung tumors in smokers].
The resistance of tumours against doxorubicin was determined in vitro and compared with their smoking habits in 94 patients (81 males and 13 females; mean age 59 [38-76] years) with non-small-cell lung tumour. Among non-smokers (n = 22) 11 tumours were resistant and 11 sensitive, while among smokers (n = 72) 57 (79%) were resistant and only 15 (21%) sensitive to doxorubicin. P-glycoprotein was measured immunohistochemically and with the monoclonal antibody JSB-1 in order to test whether there is a relationship between the prevalence of resistant tumours among smokers and the expression of P-glycoprotein. Among 22 nonsmokers only two tumours (9%) were P-glycoprotein positive, but among 72 smokers, 42 tumours (58%) were positive (P less than 0.0001). Thus, the increased amount of resistant non-small-cell lung tumours in smokers can be explained partially by an increased expression of P-glycoprotein.
Volm
M
M
Institut für Experimentelle Pathologie, Deutsches Krebsforschungszentrum Heidelberg.
Mattern
J
J
Samsel
B
B
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000230:Adenocarcinoma / Q000737:chemistry / Q000188:drug therapy / Q000453:epidemiology; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors*; D002283:Carcinoma, Bronchogenic / Q000737:chemistry / Q000188:drug therapy / Q000453:epidemiology; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000188:drug therapy / Q000453:epidemiology*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000188:drug therapy / Q000453:epidemiology; D004317:Doxorubicin / Q000037:antagonists & inhibitors; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000453:epidemiology*; D008562:Membrane Glycoproteins / Q000032:analysis; D009363:Neoplasm Proteins / Q000032:analysis; D015995:Prevalence; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology* / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D004317:Doxorubicin
Häufung von zytostatika-resistenten Lungentumoren bei Rauchern.